Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marina de Cos

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Kidney International|January 5, 2023
PD-1 inhibition in aged podocytes and glomerular diseaseMarina De Cos, Kirk N Campbell
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 21, 2026
Modeling Podocytopathies with Kidney OrganoidsMarina de Cos, Mona Zeghal, Kristin Meliambro
Kidney International Reports|April 18, 2023
Corrigendum to Novel Treatment Paradigms: Focal Segmental Glomerulosclerosis Kidney International Reports, Volume 8, Issue 1, January 2023, Pages 30-35Marina de Cos, Kristin Meliambro, Kirk N Campbell
Kidney International Reports|January 16, 2023
Novel Treatment Paradigms: Focal Segmental GlomerulosclerosisMarina de Cos, Kristin Meliambro, Kirk N Campbell
Kidney International Reports|November 29, 2023
Novel Therapies in <i>APOL1</i>-Mediated Kidney Disease: From Molecular Pathways to Therapeutic OptionsGeorge Vasquez-Rios, Marina De Cos, Kirk N Campbell
Clinical Kidney Journal|May 8, 2026
Interpreting the PISCES trial on fish oil in hemodialysis patients: lessons on trial design, biological exposure, and outcome measurementJaime Mazón-Ruiz, Marina de Cos Gomez, Paula González Bores, et al.
Atherosclerosis|November 21, 2025
Lipid lowering therapies in chronic kidney disease: A call to actionJaime Mazón-Ruiz, David Arroyo, Marina de Cos, et al.
Autoimmunity Reviews|December 13, 2021
Assessing and counteracting fibrosis is a cornerstone of the treatment of CKD secondary to systemic and renal limited autoimmune disordersMarina de Cos, Marc Xipell, Adriana García-Herrera, et al.
Nefrologia|September 27, 2022
Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progressionLuis Martín-Penagos, Gema Fernández-Fresnedo, Adalberto Benito-Hernández, et al.
Nefrologia|March 20, 2021
[Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression]Luis Martín-Penagos, Gema Fernández-Fresnedo, Adalberto Benito-Hernández, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Kidney International|January 5, 2023
PD-1 inhibition in aged podocytes and glomerular diseaseMarina De Cos, Kirk N Campbell
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 21, 2026
Modeling Podocytopathies with Kidney OrganoidsMarina de Cos, Mona Zeghal, Kristin Meliambro
Kidney International Reports|April 18, 2023
Corrigendum to Novel Treatment Paradigms: Focal Segmental Glomerulosclerosis Kidney International Reports, Volume 8, Issue 1, January 2023, Pages 30-35Marina de Cos, Kristin Meliambro, Kirk N Campbell
Kidney International Reports|January 16, 2023
Novel Treatment Paradigms: Focal Segmental GlomerulosclerosisMarina de Cos, Kristin Meliambro, Kirk N Campbell
Kidney International Reports|November 29, 2023
Novel Therapies in <i>APOL1</i>-Mediated Kidney Disease: From Molecular Pathways to Therapeutic OptionsGeorge Vasquez-Rios, Marina De Cos, Kirk N Campbell
Clinical Kidney Journal|May 8, 2026
Interpreting the PISCES trial on fish oil in hemodialysis patients: lessons on trial design, biological exposure, and outcome measurementJaime Mazón-Ruiz, Marina de Cos Gomez, Paula González Bores, et al.
Atherosclerosis|November 21, 2025
Lipid lowering therapies in chronic kidney disease: A call to actionJaime Mazón-Ruiz, David Arroyo, Marina de Cos, et al.
Autoimmunity Reviews|December 13, 2021
Assessing and counteracting fibrosis is a cornerstone of the treatment of CKD secondary to systemic and renal limited autoimmune disordersMarina de Cos, Marc Xipell, Adriana García-Herrera, et al.
Nefrologia|September 27, 2022
Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progressionLuis Martín-Penagos, Gema Fernández-Fresnedo, Adalberto Benito-Hernández, et al.
Nefrologia|March 20, 2021
[Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression]Luis Martín-Penagos, Gema Fernández-Fresnedo, Adalberto Benito-Hernández, et al.
Pageof 2